Experts discuss recent advancements in precision care for unresectable metastatic colorectal cancer, focusing on innovative treatment strategies and biomarker roles.
Advancing Precision Care in Unresectable and Metastatic Colorectal Cancer
Experts discuss the evolving role of ctDNA in managing MSI-high cancer patients, emphasizing non-operative approaches and improved treatment strategies.
In this segment, the panel addresses a key clinical question in MSI-H/dMMR mCRC: should dual immune checkpoint blockade with nivolumab plus ipilimumab be used universally upfront, or can clinicians safely sequence therapies and reserve CTLA-4 inhibition for later lines?
This segment focuses on real-world toxicity management with immune checkpoint inhibitors, particularly nivolumab plus ipilimumab, and how increasing familiarity has shaped clinician comfort and patient outcomes in MSI-H/dMMR mCRC. The discussion opens with reflections on unexpected or rare immune-related adverse events, highligting the heterogeneous and sometimes unpredictable nature of immunotherapy toxicity. Although classic toxicities such as colitis, pneumonitis, hepatitis, and rash are well recognized, panelists note that unusual presentations can occur and require clinical vigilance.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5